Research for this new therapeutic evolved from the researchers' project in the National Institutes of Health Rapid Access to Interventional Development (RAID) program that provides researchers resources and support needed for the development of new therapeutics. The NIH RAID program focuses on a subset of small molecules, including new agents that improve the activity of established chemotherapeutics.
The patented therapy, which has been licensed to TRACON, has been studied most intensively in combination with the approved chemotherapeutic Temozolomide. Methoxyamine prevents cancer cells from repairing DNA damage caused by chemotherapy, according to Steve Tan, a senior licensing manager in Case's Tech Transfer Office.
According to Michael Haag, director of biomedical licensing in Case's Tech Transfer Office, Methoxyamine could improve the anti-cancer activity of many chemotherapeutic agents, including those used for solid tumors and hematologic malignancies.
'"/>
Contact: Susan Griffith
susan.griffith@case.edu
216-368-1004
Case Western Reserve University
13-Oct-2006